Leukemia - Table of Contents alert Volume 27 Issue 12

Advertisement BD FACSCanto™ has 10-color capability. Reliable performance, accuracy, and ease of use make the latest BD FACSCanto System a perfect 10 for today's busy clinical labs. Learn how you can achieve dependable outcomes while speeding workflow and reducing training requirements with clinical multi-color flow cytometry systems from BD Biosciences. bdbiosciences.com/go/canto TABLE OF CONTENTS Volume 27, Issue 12 (December 2013) In this issue Editorial Original Articles Letters to the Editor Also new AOP Advertisement   Therapeutic Resistance in Cancer: Mechanisms, Insights and Progress This Research Topic from Frontiers in Pharmacology provides an overview of the multidimensional nature of drug resistance, as demonstrated using integrated approaches and recent advances in genomics, RNomics and proteomics. Research includes findings and perspectives on therapeutic resistance, from in vitro models and mechanistic pathways to translational and clinical research, with a particular focus on targeted therapies.  Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Advertisement NATURE REVIEWS CANCER & NATURE REVIEWS CLINICAL ONCOLOGY 2014 CALENDAR  Download the calendar for FREE As well as plundering the Nature Reviews Cancer image bank for more clinically oriented figures for our 2014 calendar, we have chosen six images and figures from our sister journal, Nature Reviews Clinical Oncology. Our calendar is freely available thanks to support from  OriGene  Editorial Top Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal S Z Usmani and A Hoering Leukemia 2013 27: 2269-2271; 10.1038/leu.2013.161 Full Text Original Articles Top MOLECULAR TARGETS FOR THERAPY JAK inhibitors suppress t(8;21) fusion protein-induced leukemia M-C Lo, L F Peterson, M Yan, X Cong, J H Hickman, R C DeKelver, D Niewerth and D-E Zhang Leukemia 2013 27: 2272-2279; advance online publication, July 1, 2013; 10.1038/leu.2013.197 Abstract | Full Text ACUTE LEUKEMIAS NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern J D E de Rooij, I H I M Hollink, S T C J M Arentsen-Peters, J F van Galen, H Berna Beverloo, A Baruchel, J Trka, D Reinhardt, E Sonneveld, M Zimmermann, T A Alonzo, R Pieters, S Meshinchi, M M van den Heuvel-Eibrink and C Michel Zwaan Leukemia 2013 27: 2280-2288; advance online publication, March 27, 2013; 10.1038/leu.2013.87 Abstract | Full Text Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia S Gachet, E Genescà, D Passaro, M Irigoyen, H Alcalde, C Clémenson, S Poglio, F Pflumio, A Janin, C Lasgi, S Dodier, M Soyer, G Duménil and J Ghysdael Leukemia 2013 27: 2289-2300; advance online publication, May 21, 2013; 10.1038/leu.2013.156 Abstract | Full Text A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling OPEN A Caldarelli, J P Müller, M Paskowski-Rogacz, K Herrmann, R Bauer, S Koch, A K Heninger, D Krastev, L Ding, S Kasper, T Fischer, M Brodhun, F-D Böhmer and F Buchholz Leukemia 2013 27: 2301-2310; advance online publication, March 19, 2013; 10.1038/leu.2013.83 Abstract | Full Text CHRONIC LYMPHOCYTIC LEUKEMIA Modeling tumor–host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy S E M Herman, X Sun, E M McAuley, M M Hsieh, S Pittaluga, M Raffeld, D Liu, K Keyvanfar, C M Chapman, J Chen, J J Buggy, G Aue, J F Tisdale, P Pérez-Galán and A Wiestner Leukemia 2013 27: 2311-2321; advance online publication, April 26, 2013; 10.1038/leu.2013.131 Abstract | Full Text STEM CELLS The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor OPEN D Karpova, K Dauber, G Spohn, D Chudziak, E Wiercinska, M Schulz, A R Pettit, J P Levesque, B Romagnoli, K Patel, E Chevalier, K Dembowsky and H Bonig Leukemia 2013 27: 2322-2331; advance online publication, September 12, 2013; 10.1038/leu.2013.266 Abstract | Full Text IMMUNOLOGY Functional characterization of Foxp3-specific spontaneous immune responses S K Larsen, S Munir, A Woetmann, T M Frøsig, N Odum, I M Svane, J C Becker and M H Andersen Leukemia 2013 27: 2332-2340; advance online publication, July 1, 2013; 10.1038/leu.2013.196 Abstract | Full Text LYMPHOMA Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity X Zhao, T Lwin, X Zhang, A Huang, J Wang, V E Marquez, S Chen-Kiang, W S Dalton, E Sotomayor and J Tao Leukemia 2013 27: 2341-2350; advance online publication, March 29, 2013; 10.1038/leu.2013.94 Abstract | Full Text MYELOMA Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study OPEN A J Jakubowiak, D S Siegel, T Martin, M Wang, R Vij, S Lonial, S Trudel, V Kukreti, N Bahlis, M Alsina, A Chanan-Khan, F Buadi, F J Reu, G Somlo, J Zonder, K Song, A K Stewart, E Stadtmauer, B L Harrison, A F Wong, R Z Orlowski and S Jagannath Leukemia 2013 27: 2351-2356; advance online publication, May 14, 2013; 10.1038/leu.2013.152 Abstract | Full Text Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276 J Schmidt, E Braggio, K M Kortuem, J B Egan, Y X Zhu, C S Xin, R E Tiedemann, S E Palmer, V M Garbitt, D McCauley, M Kauffman, S Shacham, M Chesi, P L Bergsagel and A K Stewart Leukemia 2013 27: 2357-2365; advance online publication, June 11, 2013; 10.1038/leu.2013.172 Abstract | Full Text Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs D Cirstea, T Hideshima, L Santo, H Eda, Y Mishima, N Nemani, Y Hu, N Mimura, F Cottini, G Gorgun, H Ohguchi, R Suzuki, H Loferer, N C Munshi, K C Anderson and N Raje Leukemia 2013 27: 2366-2375; advance online publication, June 28, 2013; 10.1038/leu.2013.194 Abstract | Full Text Letters to the Editor Top Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis OPEN L Bassaganyas, S Beà, G Escaramís, C Tornador, I Salaverria, L Zapata, O Drechsel, P G Ferreira, B Rodriguez-Santiago, J M C Tubio, A Navarro, D Martín-García, C López, A Martínez-Trillos, A López-Guillermo, M Gut, S Ossowski, C López-Otín, E Campo and X Estivill Leukemia 2013 27: 2376-2379; advance online publication, April 24, 2013; 10.1038/leu.2013.127 Full Text Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML K M Bernot, R F Siebenaler, S P Whitman, N A Zorko, G G Marcucci, R Santhanam, E H Ahmed, M Ngangana, K K McConnell, J S Nemer, D L Brook, S K Kulp, C S Chen, D Frankhouser, P Yan, R Bundschuh, X Zhang, A M Dorrance, K E Dickerson, D Jarjoura, W Blum, G Marcucci and M A Caligiuri Leukemia 2013 27: 2379-2382; advance online publication, May 10, 2013; 10.1038/leu.2013.147 Full Text Aberrant expression of CCR4 in diffuse large B-cell lymphoma, not otherwise specified S Nakayama, T Yokote, Y Hirata, K Iwaki, T Akioka, T Miyoshi, N Hiraoka, A Takayama, U Nishiwaki, Y Masuda, Y Nishimura, M Tsuji and T Hanafusa Leukemia 2013 27: 2382-2385; advance online publication, April 24, 2013; 10.1038/leu.2013.128 Full Text Galectin-3 in pre-B acute lymphoblastic leukemia F Fei, H Abdel-Azim, M Lim, A Arutyunyan, M von Itzstein, J Groffen and N Heisterkamp Leukemia 2013 27: 2385-2388; advance online publication, June 13, 2013; 10.1038/leu.2013.175 Full Text SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t(11;14) translocation, CCND1 expression and an adverse prognosis M Meggendorfer, W Kern, C Haferlach, T Haferlach and S Schnittger Leukemia 2013 27: 2388-2391; advance online publication, May 7, 2013; 10.1038/leu.2013.141 Full Text Vertebral augmentation in the treatment of pathologic compression fractures in 792 patients with multiple myeloma OPEN E Erdem, R Samant, S F Malak, W C Culp, A Brown, L Peterson, S Lensing and B Barlogie Leukemia 2013 27: 2391-2393; advance online publication, June 3, 2013; 10.1038/leu.2013.162 Full Text Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients S Weissmann, A Roller, S Jeromin, M Hernández, M Abáigar, J M Hernández-Rivas, V Grossmann, C Haferlach, W Kern, T Haferlach, S Schnittger and A Kohlmann Leukemia 2013 27: 2393-2396; advance online publication, July 17, 2013; 10.1038/leu.2013.218 Full Text Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application OPEN L I Aronson, E L Davenport, F Mirabella, G J Morgan and F E Davies Leukemia 2013 27: 2397-2403; advance online publication, May 14, 2013; 10.1038/leu.2013.150 Full Text In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia M Strullu, A Caye, B Cassinat, O Fenneteau, F Touzot, T Blauwblomme, R Rodriguez, S Latour, A Petit, V Barlogis, C Galambrun, T Leblanc, A Baruchel, C Chomienne and H Cavé Leukemia 2013 27: 2404-2407; advance online publication, July 4, 2013; 10.1038/leu.2013.203 Full Text Granulocyte colony-stimulating factor receptor T595I (T618I) mutation confers ligand independence and enhanced signaling H M Mehta, T Glaubach, A Long, H Lu, B Przychodzen, H Makishima, M A McDevitt, N C P Cross, J Maciejewski and S J Corey Leukemia 2013 27: 2407-2410; advance online publication, June 6, 2013; 10.1038/leu.2013.164 Full Text Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia Q Jiang, L-P Xu, D-H Liu, K-Y Liu, R P Gale, M-J Zhang, B Jiang, X-H Zhang, Y Wang, S-S Chen, X-Y Zhao, H Chen, H Jiang, Y-H Chen, W Han, Y-Z Qin, Y-R Liu, Y-Y Lai, M Lv and X-J Huang Leukemia 2013 27: 2410-2413; advance online publication, May 23, 2013; 10.1038/leu.2013.159 Full Text Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children D Tomizawa, A Tawa, T Watanabe, A M Saito, K Kudo, T Taga, S Iwamoto, A Shimada, K Terui, H Moritake, A Kinoshita, H Takahashi, H Nakayama, K Koh, H Kigasawa, Y Kosaka, H Miyachi, K Horibe, T Nakahata and S Adachi Leukemia 2013 27: 2413-2416; advance online publication, May 16, 2013; 10.1038/leu.2013.153 Full Text Associations between genome-wide Native American ancestry, known risk alleles and B-cell ALL risk in Hispanic children K M Walsh, A P Chokkalingam, L-I Hsu, C Metayer, A J de Smith, D I Jacobs, G V Dahl, M L Loh, I V Smirnov, K Bartley, X Ma, J K Wiencke, L F Barcellos, J L Wiemels and P A Buffler Leukemia 2013 27: 2416-2419; advance online publication, April 25, 2013; 10.1038/leu.2013.130 Full Text Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia L Lo Nigro, E Mirabile, M Tumino, C Caserta, G Cazzaniga, C Rizzari, D Silvestri, B Buldini, E Barisone, F Casale, M Luciani, F Locatelli, C Messina, C Micalizzi, A Pession, R Parasole, N Santoro, G Masera, G Basso, M Aricò, M Valsecchi, A Biondi and V Conter on behalf of AIEOP—Scientific Committee of ALL Leukemia 2013 27: 2419-2421; advance online publication, May 14, 2013; 10.1038/leu.2013.149 Full Text Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance D Zamarin, S M Devlin, M E Arcila, H Landau, A Lesokhin, N Lendvai, D J Chung, D Chimento, J Weltz, D Babu, S Giralt and H Hassoun Leukemia 2013 27: 2422-2424; advance online publication, April 23, 2013; 10.1038/leu.2013.126 Full Text Advertisement Read some of BMT's most downloaded articles of 2013 so far: - Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics  - More than skin deep? Emerging therapies for chronic cutaneous GVHD  - Diagnosis of acquired aplastic anemia Visit www.nature.com/bmt to sign up for the monthly e-Alert and to submit your paper.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.